KCT0006567
Recruiting
未知
A Single-center, Single-arm, Open-label, Phase I/II Study to evaluate the safety and efficacy of Autologous activated lymphocyte Injection in Stage 4 Solid Cancer Patient.
Gsamhospital0 sites240 target enrollmentTBD
ConditionsNeoplasms
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Neoplasms
- Sponsor
- Gsamhospital
- Enrollment
- 240
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •? Stage 4 solid cancer patients over 19 years of age
- •? Those whose chemotherapy has been discontinued for at least 1 month in the past or
- •Those who are estimated not to receive chemotherapy for 1 month until the cell therapy is administered,
- •(Only those who have received topical treatment that does not contain anticancer drugs within 1 month are allowed)
- •? Those who have a negative serum pregnancy test 7 days before the start of the test (females of childbearing age)
- •? Those who agreed to use appropriate contraception during the test period (women of childbearing age)
- •? ECOG PS 0, 1, 2 persons
- •? Those whose life expectancy is at least 3 months or longer as judged by the clinician
- •? Those who have adequate kidney function, liver function, and bone marrow function in the blood test (WBC\=3000/µl, platelet\=75000/µl, creatinine\=1\.5mg/?, total bilirubin\=1\.5mg/?, AST(GOT) and ALT( GPT) \=2\.5\* upper limit of normal, albumin\>3\.0g/dL, hemoglobin, etc. in clinical pathology are used as reference values ??only)
- •? Measurable disease factor based on RECIST v 1\.1
Exclusion Criteria
- •? Men and women under 19 years of age
- •? Patients who received systemic corticosteroids and immunosuppressants within at least 4 weeks prior to the start of administration of the test drug in this study
- •? Patients who have immunodeficiency disease due to exertion or who are positive for AIDS antibody
- •? If you currently have an acute infection
- •? Patients who took systemic anticancer drugs within at least 4 weeks before the start of the test drug administration in this study, and systemic anticancer drugs include treatments that may affect the treatment of other cell therapy drugs such as PD\-1inhibitor.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A study of the effect of hydrogen peroxide foam in patients with bacterial vaginosisBacterial vaginosisMedDRA version: 18.1Level: PTClassification code 10004055Term: Bacterial vaginosisSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]EUCTR2015-003356-51-SEZelmic AB30
Active, not recruiting
Not Applicable
Clinical Study To Evaluate the Recommended Dose, Safety, Pharmacokinetics and Efficacy of vemurafenib (RO5185426) in Paediatric Patients 12 to 17 Years Old With BRAFV600 Mutation PositiveMetastatic MelanomaMedDRA version: 17.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-000874-67-PLF. Hoffman-La Roche Ltd.20
Active, not recruiting
Phase 1
Clinical Study To Evaluate the Recommended Dose, Safety, Pharmacokinetics and Efficacy of vemurafenib (RO5185426) in Paediatric Patients 12 to 17 Years Old With BRAFV600 Mutation PositiveMetastatic MelanomaMedDRA version: 14.1Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-000874-67-GBF. Hoffman-La Roche Ltd.6
Active, not recruiting
Phase 1
Clinical Study To Evaluate the Recommended Dose, Safety, Pharmacokinetics and Efficacy of vemurafenib (RO5185426) in Paediatric Patients 12 to 17 Years Old With BRAFV600 Mutation PositiveMetastatic MelanomaMedDRA version: 14.1Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-000874-67-DEF. Hoffman-La Roche Ltd.20
Active, not recruiting
Phase 1
Clinical Study To Evaluate the Recommended Dose, Safety, Pharmacokinetics and Efficacy of vemurafenib (RO5185426) in Paediatric Patients 12 to 17 Years Old With BRAFV600 Mutation PositiveEUCTR2011-000874-67-ESF. Hoffman-La Roche Ltd.6